Robert Charles Breedlove - 19 May 2025 Form 4 Insider Report for Phathom Pharmaceuticals, Inc. (PHAT)

Reporting relationship: Principal Accounting Officer
Issuer ticker: PHAT
Reported as of: 19 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 May 2025, 17:17:36 UTC
Prior SEC filing: 06 May 2025
Next SEC filing: 18 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Robert Charles Breedlove

Key filing fact

Robert Charles Breedlove filed Form 4 for Phathom Pharmaceuticals, Inc. (PHAT) on 21 May 2025.

Key facts

This page summarizes Robert Charles Breedlove's Form 4 filing for Phathom Pharmaceuticals, Inc. (PHAT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 May 2025, 17:17.

Change

Previous filing in this sequence was filed on 06 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002066645 Primary reporting owner

Breedlove Robert Charles

Relationship: Principal Accounting Officer
Address: C/O PHATHOM PHARMACEUTICALS, INC., 100 CAMPUS DRIVE, SUITE 102, FLORHAM PARK
Signature: /s/ Robert Charles Breedlove
Signature date: 21 May 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PHAT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +33,000
Change %
Price: $0.000000
Shares after: 33,000
Date: 19 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,000
Exercise price: $4.39
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest with respect to 25% of the shares of common stock on May 19, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.